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Abstract
Background: While venture funding has been applied to biotechnology and health in high-income countries, it is
still nascent in these fields in developing countries, and particularly in Africa. Yet the need for implementing
innovative solutions to health challenges is greatest in Africa, with its enormous burden of communicable disease.
Issues such as risk, investment opportunities, return on investment requirements, and quantifying health impact are
critical in assessing venture capital’s potential for supporting health innovation. This paper uses lessons learned
from five venture capital firms from Kenya, South Africa, China, India, and the US to suggest design principles for
African health venture funds.
Discussion: The case study method was used to explore relevant funds, and lessons for the African context. The
health venture funds in this study included publicly-owned organizations, corporations, social enterprises, and
subsidiaries of foreign venture firms. The size and type of investments varied widely. The primary investor in four
funds was the International Finance Corporation. Three of the funds aimed primarily for financial returns, one
aimed primarily for social and health returns, and one had mixed aims. Lessons learned include the importance of
measuring and supporting both social and financial returns; the need to engage both upstream capital such as
government risk-funding and downstream capital from the private sector; and the existence of many challenges
including difficulty of raising capital, low human resource capacity, regulatory barriers, and risky business
environments. Based on these lessons, design principles for appropriate venture funding are suggested.
Summary: Based on the cases studied and relevant experiences elsewhere, there is a case for venture funding as
one support mechanism for science-based African health innovation, with opportunities for risk-tolerant investors
to make financial as well as social returns. Such funds should be structured to overcome the challenges identified,
be sustainable in the long run, attract for-profit private sector funds, and have measurable and significant health
impact. If this is done, the proposed venture approach may have complementary benefits to existing initiatives and
encourage local scientific and economic development while tapping new sources of funding.
Background
Financing the development and deployment of innova-
tive health products to tackle global health problems –
including drugs, vaccines, medical devices and new pro-
cesses – is an ongoing enterprise with diverse partici-
pants. For instance, more than 1 billion dollars have
been invested by philanthropists and donors into global
Product Development Partnerships (PDP’s), and these
have shown significant progress in the development of
innovative health solutions [1]. Direct financing of global
health innovations is being carried out by many others,
including many of the G20 nations; United Nations
agencies; the Global Fund to Fight AIDS, Tuberculosis
and Malaria; philanthropists like the Bill & Melinda
Gates Foundation; and multilateral donors and funding
initiatives. According to the G-FINDER 2009 report,
global neglected disease R&D funding in 2008 came
mainly from public and philanthropic donors (87.6%;
$2.59B), with a significant minority from the pharma-
ceutical industry (12.4%; $0.37B) [2].
Yet there remains a health innovation financing gap in
Africa, as none of these funds and initiatives have
focused on creating sustainably-financed health
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[3]. Funding health innovation in Africa has largely been
left to African governments themselves, supported by
donors, but this has been done indirectly through small
innovation funds like those in Uganda (see the Uganda
paper in this BMC series) and similar small funds in
Kenya and Ghana. Since these are not specific to health,
the bulk of funding has gone to fields other than health
R&D which are perceived as less risky. Some interna-
tional funds also flow into African universities with
strong health research programs, such as Makerere Uni-
v e r s i t yi nU g a n d aa n dt h eU n i v e r s i t yo fC a p eT o w ni n
South Africa. While relatively small and not well docu-
mented, such funds can play a role in strengthening
African health research capacity [4].
One area that has barely been exploited in financing
health innovation in Africa is venture capital. Venture
capital (VC) refers to provision of finance, managerial
oversight and strategic expertise to enterprises with
novel, commercially-viable ideas. VC has catalyzed new
business models and technologies to deliver novel, high-
risk innovations in health in the developed world, and
has been an important source of funding for health and
biotechnology companies [5]. In the West, venture capi-
tal was used to pioneer health products in such compa-
nies as Genentech, Amgen, and Genzyme.
Analysis based on empirical data has long raised ques-
tions about whether and under what conditions VC
firms add sufficient value to justify the ownership stakes
they take in fledgling companies [6]. However, they have
indisputably been key catalysts in the success of many
companies that are now household names, and they
bring a range of strengths to developing new science-
based businesses. Venture investors can help to identify
promising early-stage opportunities, invest in opportu-
nities too risky for banks, support development of new
firms, and network new firms with markets and mentors
[7]. They develop specialized expertise to select, moni-
tor, and support investments, and thus reduce risk for
investors into VC funds. Venture investors may thus be
able to transform promising R&D into viable products
and services – supplementing public funds by channel-
ing private capital toward global health innovation.
What is the potential of venture funding for support-
ing science-based African health innovation? The main
objective of traditional venture capitalists is to achieve
high financial returns, to counterbalance the high risk
involved. A complementary objective of other health
innovation funders is to achieve high social returns, e.g.
improved access to and quality of health products, eco-
nomic development, and ultimately improved health
outcomes. Can these two objectives both be met in
designing venture funding for science based health inno-
vation in Africa – whether in a design for health-
oriented VC firms, or in a design for an overall health
innovation funding system with firms and funders
collaborating?
Africa has increasingly been recognized as containing
a number of countries offering the potential for high
investment returns [8]. In this paper, when we speak of
“Africa”, we focus on the more economically and politi-
cally stable subset of sub-Saharan African countries
which are achieving steady economic growth, deepening
democracy, improving governance, and decreasing pov-
erty [9]. We include South Africa, while recognizing
that as the leader in the continent in technological and
economic terms it has more opportunities and resources
for venture funding.
More than 155 public and private venture capital
firms managing 273 funds and investments in a wide
variety of sectors in 49 African countries were identified
in a survey in 2005 [10]; venture activity has grown sig-
nificantly since then. These funds are a mix of interna-
tional and domestic venture funds from governments,
donors, and the private sector.
However, the majority of existing funds invest in tra-
ditional sectors such as agriculture, mining and energy.
Except for Bioventures in South Africa, which has
invested roughly 12 million US dollars in life sciences,
none of these funds has focused on life sciences
research and development (R&D) – as e c t o rw i t hl o n g
timescales and potentially high technology and market
risk [11].
Two issues of concern to investors are risks and the
existence of viable opportunities [12]. Yet contrary to
international press images of Africa as a land of poverty,
war and disease, risks are arguably not too dissimilar to
risks experienced by venture capital investors elsewhere
in the world [13]. And while poverty and lack of infra-
structure and experienced human resources amplify
these risks, the growth of African venture capital in
other sectors suggests that risks can be addressed
through evaluation, monitoring, and risk mitigation
steps. (We discuss risks at greater length in the “Obser-
vations and analysis” section later.)
Regarding viable opportunities, a 2007 report by the
IFC identified health innovation as an investment
opportunity in health in Africa [3]. A survey we con-
ducted identified 25 prospective technologies in sub-
Saharan Africa outside of South Africa which might be
suitable for licensing and further development (see the
table in the Introductory article in this BMC series, and
[14] for further discussion). An example is Nibima, a
product from a traditional plant Cryptolepis sanguino-
lenta, being developed to treat malaria by scientists at
the Centre for Scientific Research into Plant Medicine
in Mampong, Ghana. Another is a visually-readable por-
table malaria dipstick test being developed at the
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does not require serum, and is non-invasive. While
these examples may or may not prove commercially
viable, they do suggest the existence of viable opportu-
nities for venture funds to consider.
In this paper, we offer one of the first studies to sys-
tematically examine venture financing as a potential
form of funding for African health R&D. We base our
analysis on five original case studies of VC firms that
have funds invested in health R & D. To our knowledge,
this sample contains all health R&D focused venture
capital firms based in the developing world created prior
to 2007. Three of the firms have operations in Africa:
BioVentures (South Africa), Bridgeworks Africa (Kenya),
and Acumen Fund (multiple locations in Africa, Asia,
and Latin America, with a head office in New York).
We complemented these with two additional case stu-
dies, one each from China and India: BioVeda Capital
(China), and APIDC-VE (India). (Where the firm has
only one fund of relevance to this paper, we use the
name of the firm to indicate its fund for ease of
exposition.)
Funds that focus on health delivery alone were
excluded, as these have received attention elsewhere [3].
All case studies were based on a combination of semi-
structured interviews with key informants, site visits,
and primary and secondary literature analyses. We con-
ducted dozens of interviews with informed consent of
fund managers and investees across the five funds and
complementary stagnant technology sites, and con-
ducted site visits to the fund and stagnant technology
sites between 2007 and 2009; secondary analysis was
also done of peer-reviewed literature, articles, news
items and web sites. Representatives of the funds were
asked to fact-check the case studies; the analysis and
interpretation is our own. All quotes are from the inter-
views unless otherwise noted, and with permission. This
study was approved by the Office of Research Ethics of
the University of Toronto.
This paper will be of interest to decision-makers in
health and development who are open to new
approaches tapping private capital, and to entrepreneurs
and capital providers who may wish to refine, advocate
for, or finance appropriate venture funding. In studying
the five venture capital firms, lessons are drawn with
respect to considerations for designing African venture
funds to support science-based health innovation.
Options to support such venture funds are then sug-
gested, including complementary developments such as
innovation and convergence centers. The venture funds
discussed in this paper, along with the options suggested
for creating and supporting future funds, suggest a
viable role for VC as a funding source for African health
innovation.
Discussion
Description of venture funds
In this section, we describe five original case studies of
VC firms that have funds invested in health R&D. Three
of the firms have operations in Africa; complemented
with two additional firms from China and India. These
VC firms are subsequently analyzed to draw lessons for
future African funds investing in health R&D. The firms
are summarized in Table 1.
BioVeda Capital
Since the early 1990s, international VC funds have
existed in China for IT and other sectors. But the Bio-
Veda China Fund, formed in 2005, was the first interna-
tional venture fund directed at the life sciences in
China. This Shanghai-based fund was initially founded
by Harvard-trained “sea turtle” (emigrant who returned
to China) Dr. Zhi Yang who had over twenty years of
biotech and private equity experience, and seven life
sciences start-ups under his belt. Initial investors in the
original $US32 million Bioveda China fund included the
IFC, Temasek Holdings (Singapore) and HBM BioVen-
tures (Switzerland).
BioVeda China has focused on late-stage development
and scaling up of existing companies which already have
revenues, and as such has characteristics of private
equity. However, there are a few investee companies
with products in Phase I/II trials. To mitigate risk,
Table 1
Firm Name BioVeda China Bridgeworks
Africa
APIDC-VE BioVentures Acumen Fund
Location Shanghai, China Nairobi,
Kenya
Hyderabad, India Cape Town,
South Africa
Hyderabad, Nairobi and
Karachi, Pakistan
Total Fund
Size
~$150M ~$2M ~$40M ~$12M ~$50M
Number of
Investments
12 15 15 8 50
Key Investors IFC, Gov. of Shanghai, Temasek Holdings, HBM
Ventures, Lilly Asian Ventures
BioVision
Foundation
IFC, APIDC,
VenturEast India
IFC, Gensec
Bank
Rockefeller Foundation, Cisco
Systems Foundation
Date Founded 2005 2004 2003 2002 2001
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sciences – industrial biotechnology, biologics, logistics
and medical devices – and share the characteristic of
leveraging China’s large domestic demand.
One major challenge the fund has faced is the Chinese
regulatory environment. As founder Zhi Yang noted in
2007, “Knowing people is very important. We keep
track and grade all the CEOs [in China].”
BioVeda China brought banks in the United States as
co-investors, created a scientific advisory board for
scientific and ethical issues, and engaged the local
Shanghai government to provide both financial and poli-
tical capital. A dual-fund model via incorporating in the
Cayman Islands allows BioVeda China to navigate
Chinese foreign direct investment regulations, and exit
its investments internationally. Of BioVeda’s portfolio of
twelve investee companies, six have successfully exited
and realized returns (4 IPOs and 2 acquisitions).
Although the fund is for-profit, BioVeda China serves
as a pioneering model of how international VCs and lar-
ger institutional investors can invest in a gateway to
R&D in emerging markets. The initial smaller $US32
million fund provided proof of concept for the subse-
quent funds. In 2007, a second $US100 million fund
(BioVeda China II) was raised.
By focusing on late-stage firms with existing revenue
streams, diversifying its portfolio, and attracting talented
“sea turtles”, Bioveda China demonstrates how investors
can pave the way for larger, more high-risk, innovation-
focused funds – and shows how a for-profit fund in an
emerging economy with a strong research base can cre-
ate new health technologies.
APIDC-VE
The Andhra Pradesh Industrial Development Corpora-
tion - VentureEast Biotechnology Venture Fund (abbre-
viated to “APIDC-VE”) was founded in 2003 in
Hyderabad. APIDC-VE is India’s first VC fund focused
on biotech. APIDC had previously partnered with the
venture group VentureEast for a multi-sectoral VC fund.
Having enjoyed prior success with their multi-sector VC
fund, APIDC-VentureEast was able to leverage their
reputation to raise $US40 million for a biotech-focused
fund, through domestic and foreign investors.
The major domestic investors were led by the Andhra
Pradesh state government, and the Indian Federal Gov-
ernment’s Technology Development Board which gave
$US7.5 million to the project. The key foreign investor
was the IFC, which provided technical advice, interna-
tional networks, and a positive reputational signal that
attracted follow-on investors such as CITCO, a global
financial service company, and Norfund, Norway’s devel-
opmental bank.
The fund was fully invested in 2005, with a planned
life of 10 years. It aimed to commercialize Indian
biotechnology investments in a for-profit way, but also
to have a ripple effect of broader domestic benefits. The
fund had some freedom to pursue social benefits
through its choice of investees; its public and develop-
mental investors influenced its character.
The fund proactively recruited investments by going
into universities years before projects were ready for
commercialization. APIDC-VE’s portfolio consists of
mostly early-stage companies, but also includes invest-
ments outside of India that have relevance to the Indian
market. Investees are a mix of R&D and healthcare
infrastructure firms.
One innovative investee was Neurosynaptic. The firm
specializes in developing telemedicine diagnostic equip-
ment for rural areas, and with a rapidly-expanding net-
work of over 150 centers has the potential to grow into
one of the largest such networks in the world. The
World Economic Forum selected Neurosynaptic as one
of their Technology Pioneers of 2008.
Created in collaboration with IIT Madras, “ReMeDi,”
(Remote Medical Diagnostics) is a portable device com-
bining diagnostics for temperature, blood pressure, pulse
oximetry and ECG, with telemedical software that trans-
mits information to a doctor for diagnosis. APIDC-VE
helped Neurosynaptic partner with the Apollo chain of
hospitals to develop a business model targeted at rural
communities. Poor villagers cannot afford the time and
money to travel for correct diagnosis to large urban cen-
ters. Neurosynaptic worked with local organizations to
create sustainable franchises that would allow the rural
operator to earn the revenues necessary to operate a tel-
emedicine center in their village. 75% of patients who
are diagnosed in the village by ReMeDi now get treat-
ment in their village.
The CEO of Neurosynaptic, Sameer Sawarkar, credits
APIDC-VE as being distinct from other investors in that
they are “looking at this whole segment as a long-term
segment that is completely untapped. And they’re will-
ing to experiment and learn new processes that can be
applied to the sector as a whole, as opposed to being
interested in only investment in the sense of the tradi-
tional venture capitalists.” The VCs at APIDC-VE echo
these sentiments: “We’ll do a deal in a sector even if we
have to create it from scratch… India itself is such a
huge market. If we can create products and services for
it, we can sustain many funds like [this].”
APIDC-VE illustrates how emerging economies with a
strong technical base such as India provide fertile
ground for funds. However, funds still need to adapt to
local contexts, and look for competitive advantages such
as providing a brokering service for large foreign inves-
tors. A flexible approach is key when transplanting ven-
ture funding. While the fund’s financial results will not
become clear until it starts exiting its investments
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like Neurosynaptic suggest promise.
BioVentures
CEO Heather Sherwin headed Bioventures, the first life
sciences VC in sub-Saharan Africa. A cell biologist
trained in South Africa, Sherwin persuaded her financial
services employer that they needed a biotech VC fund
to complement their successful IT VC fund. This 80
million rand (~$US 12M) biotech fund made initial
investments in 8 home-grown companies between 2002
and 2004, with most of the investments having been
exited by 2009.
Seed financing came from the IFC. Bioventures was
reportedly the IFC’s first-ever biotechnology fund invest-
ment. Bioventures’ investees are focused on R&D-inten-
sive medical devices, drugs, and natural products –
categories chosen partly due to South Africa’si n a b i l i t y
to compete with China and India on manufacturing
costs for less R&D-intensive products.
One such investee, Disa Vascular, is now a global
player with over 30 employees and several million dol-
lars in annual revenue. The firm produces several niche
products for treatment of coronary and peripheral
artery disease, including coronary stents and diagnostic
catheters that are marketed in the European Union.
Notably, Disa conducts clinical trials in South Africa –
a testament to its ability to attract clinician interest
despite the strong presence of multinationals. Bioven-
tures helped Disa by raising operating capital, advising
on a niche R&D-intensive strategy with high market
entrance barriers, and linking them to international
partners. Follow-on financing of ~$US1 million came
from international investors such as Lacuna SICAV
(Belgium) in 2007.
Other successful investees included PlatCo and Shi-
moda, two drug development companies focused on pla-
tinum-based anti-cancer compounds and enhanced
generics respectively. Both were reportedly sold to US-
based Abraxis BioScience in 2008 for $US15 million.
While the fund had a for-profit focus, its strategies
and learnings are applicable to future funds with social
impact aims. It actively sought out exciting R&D, rather
than waiting for business plans to come to them – 8o f
300 potential investments were supported, with invest-
ments sought upstream in universities. The fund used
risk-mitigating mechanisms including provisions to
increase its equity share if an investee didn’tm e e tp r e -
viously-agreed performance milestones – as h o c kf o r
entrepreneurs used to milestone-free government fund-
ing. Challenges included competing against multina-
tionals with higher credibility and funding, the relative
lack of an entrepreneurial culture in South African
research institutes, and exchange controls that made
selling companies internationally difficult.
The small fund size prevented follow-on investments
into investee companies, which meant Bioventures was
forced to give up equity, or to sell investee companies
prematurely to international purchasers. Risk-averse
local investors combined with long timeframes and high
risk associated with the life sciences made local follow-
on investments difficult, especially since some investors
had unrealistic expectations about financial returns.
Bioventures illustrates how life sciences VC can work
in strong sub-Saharan African economies. At the same
time, the fund’s experience shows how achieving social
impact is more challenging. One investee had a promis-
ing HIV/AIDS drug discovery platform in addition to a
pain program. Eventually the fund and the firm con-
cluded that they could not afford to keep siphoning
money to R&D. As CEO Sherwin said, “We canned the
AIDS program in favor of pain and oncology programs
whose IP could be sold to international investors…If
you follow your pure VC mandate, you cannot invest in
TB or HIV companies. You’re not going to get your
returns.”
Two key lessons from Bioventures were the fund’s
inadequate size, and the fund’s inability to pursue
mixed-return investments due to the kinds of investors
the fund had. Sherwin suggested “mixed funds” as the
way forward – funds that would have investment capital
with a lower expectation of financial return, and benefit
from technical assistance and other support that would
make investing into areas targeting health impacts more
feasible. (For further details, see the Bioventures paper
in this BMC series [15].)
Bridgeworks Africa
Bridgeworks Africa was the first Kenyan life sciences
focused VC fund. However, unlike traditional VC mod-
els, Bridgeworks opted to take a non-profit approach
and partner with a single institution, the International
Centre for Insect Physiology and Ecology (ICIPE). As
the brainchild of Dr. Hans Herren, ICIPE’sD i r e c t o r
from 1994 to 2005, Bridgeworks hoped to commercialize
the rich research base that ICIPE had developed since
its inception in 1970 through partnerships with
researchers from over 70 countries.
ICIPE’s focus was on developing tools and strategies
for managing arthropods to benefit the health of
Kenyans. Particularly noteworthy were its attractant-
repellent technologies for controlling tsetse flies and
mosquitoes, which are the biological vectors for agents
causing trypanosomiasis and malaria. The Institute
reportedly had 8 patents related to these technologies.
Bridgeworks Africa received seed funding of $US1.5
million in 2004 and spun off from the Swiss-based Bio-
Vision Foundation that ICIPE’s then-Director Herren
had founded in 1998. What began as a promising
experiment became mired in problems. As of 2009,
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operation was no longer active.
Raising capital was challenging due to lack of interest
by the government, stringent criteria of international
development banks, and lack of linkages to the Kenyan
diaspora. It was difficult to reconcile traditional NGO
models with Bridgeworks’ new “social VC” model.
Bridgeworks faced resistance from the researchers of
ICIPE, weak institutional frameworks, and regulatory
inefficiencies in moving projects forward.
The fund may have also spread its limited resources
too thin. It distributed its scarce capital across fifteen
investments, and had some of its senior staff managing
investments remotely from Switzerland. By associating
itself primarily with one research institute, Bridgeworks
may have had limited exposure to the best investment
opportunities.
Many of ICIPE’s most promising technologies such as
its attractant-repellent technologies simply did not have
scalable business models, especially since their target
market included nomadic and rural communities.
Although Dr. Hassanali, one of the ICIPE’s lead attrac-
tant-repellent researchers, believed that involving com-
panies would increase the pace of dissemination and get
“faster and widest impact,” the profits were not
significant.
“ICIPE has focused largely on small-scale farmers.
That was the philosophy right from the start… Is a i d
‘Let’s develop all these products targeting different eco-
n o m i cs t r a t ai nE a s t e r nA f r i c a … [Bridgeworks Africa]
didn’t show too much interest… In some cases, it’sb e t -
ter to let communities take over everything. In other
cases these technologies need entrepreneurs, but they
need to be of a special kind – entrepreneurs who don’t
want to be millionaires or billionaires overnight.”
Bridgeworks Africa illustrates the extreme challenge of
operating a VC fund in sub-Saharan Africa. The fund
achieved modest success in evaluating and identifying
technologies, but was unable to capitalize on this. Funds
ignore at their own peril the risk of overreaching with
limited resources, and the importance of adapting busi-
ness models to local contexts.
Acumen Fund
Acumen Fund is a social VCf u n dw h i c hi n v e s t sf o r
both social and financial returns. It has offices in New
York, India, Pakistan, and Kenya, and a significant focus
on health. Founded in 2001 by Jacqueline Novogratz, a
former investment banker with a passion for microfi-
nance, Acumen initially provided grants to R&D-focused
organizations. However, these technologies failed to
reach the market, which led Acumen to focus on distri-
bution and delivery, and shift towards market-informed
investing and a more hands-on approach.
Acumen believes that well-crafted equity coupled with
metrics “forces the financial discipline necessary for
social enterprises to achieve sustainability.” Indeed, this
strategy has paid off. Its investees now span the entire
health system from manufacturing to financing to deliv-
ery, and some have become global players.
One investee, Botanical Extract EPZ Limited (BEEPZ,
formerly ABE) works with 3,500 farmers in East Africa
producing artemisinin for 60 million doses of malaria
treatment yearly. The cost of artemisinin combination
therapies is more than that of conventional drugs due to
lack of supply; BEEPZ is helping to resolve this supply
crisis. Another, A to Z Textile Mills, produces 25 mil-
lion long-lasting bed-nets per year that provide protec-
tion to nearly 40 million people, while employing 7000
Tanzanians. (See the A to Z paper in this BMC series.)
The fund recognizes that it may take longer for invest-
ments with social impact to provide a return on invest-
ment, and may require more support. Its innovative
fellow and alumni programs tap talent from the devel-
oped world to support investees and develop manage-
ment, providing inexpensive yet experienced advice.
Acumen’s local presence through subsidiaries in India,
Kenya and Pakistan allows it to monitor local opportu-
nities and conditions. Its rigorous selection methodology
and hands-on approach to training human capital and
designing business strategies have helped achieve
remarkable social impact, as quantified by metrics such
as the tens of millions helped through investees like
BEEPZ and A to Z. (For more on Acumen Fund’s health
investment portfolio and process, see [16].)
Observations and analysis
Based on the above case studies and subsequent analy-
sis, we discuss design considerations for potential Afri-
can venture funding for science-based health innovation.
(Our analysis complements other initiatives for African
funding for science-based health innovation, e.g. [17].)
Types of venture firms
Based on the above cases, three categories of venture
capital firms can be identified, based on their approach
and goals:
1.Private VC (pure financial). Independent venture
capitalists structured as corporations, with a primary
aim of financial returns (Bioventures and Bioveda
China).
2. Public VC (hybrid financial and development).
Publicly-financed venture capitalists consisting of
supra-national or government funded venture capital
programs, managed by professional venture capital
managers (APIDC-VE). Along with financial returns,
they have a mandate for local economic development.
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venture capitalists like Acumen Fund have a man-
date to invest for combined financial and social
returns. Bridgeworks Africa had a similar combined
mandate, though it achieved less success.
A common investor for all venture firms except Acu-
men Fund and Bridgeworks was the International
Finance Corporation (IFC), and the IFC has co-invested
with Acumen Fund. All firms operated within a single
country, except for Acumen Fund which has country
offices; understanding local business and regulatory con-
texts well enough to develop new technology solutions
may require a deep level of local knowledge and
experience
Types of fund risk
When considering whether to set up or invest in a
health venture fund in Africa, numerous risks become
apparent. These risks can be divided into three cate-
gories, relating to sector, location, and firm. (Risks relat-
ing to particular investments of a health venture fund
are considered briefly in the next section. A broader
view of barriers to health technology R&D in the devel-
oping world can be found in [18] and [19].)
Sector: investing in R&D anywhere in the world is a
risky proposition almost by definition. Many new health
technologies pose particular difficulties due to lengthy
time scales and regulatory and clinical requirements.
Within the health technology sector, neglected disease
R&D suffers from a lack of profitable markets.
Location: risks have been perceived as especially high
for most of the African continent, though this is chan-
ging for the best-governed countries [9]. Challenges of
bureaucratic inefficiency, corruption, and poor infra-
structure endure. There is little early-stage government
funding to stimulate innovation activity and de-risk pri-
vate and VC investment, though this is gradually chan-
ging in some countries such as Uganda. With respect to
financial markets, it may be difficult for international
investors to repatriate funds; this was an issue identified
by Bioventures management, with respect to exchange
controls. There has been a lack of IPO and other exit
opportunities on the continent. There is also a local lack
of experienced life science entrepreneurs and mentors.
Firm: there may be a trust problem if the venture firm
is itself new and unknown to investors – it is interesting
to note that all venture firms studied had management
with substantial experience in developed countries. Fund
lifespans may be an issue, as well as small fund sizes
which limit capacity. Both Bridgeworks and Bioventures
faced challenges due to limited capital for initial and fol-
low-on investments; the firm management felt that their
success had been concomitantly limited.
Investment strategy
The type of investments that these firms made varied
widely, ranging from R&D in biotechnology to invest-
ments in pharmaceuticals, medical devices, and manu-
facturing. Each type of investment has its associated
risks and rewards, and these must be considered in
detail to assess a fund’s viability. Such work is already
underway with respect to particular areas, such as phar-
maceutical innovation in Africa [20]; initial work on sev-
eral other health sectors has also been done [3].
The stage of investment differed between cases. While
Bioveda focused on late-stage development of existing
companies, Bridgeworks and Bioventures provided early
seed capital to their investees, often investing in new
companies built around technologies rather than in
existing companies.
The venture capital firms, already themselves con-
strained by lack of resources, had to be more involved
in developing investees than might be typical in North
America and Europe. This naturally requires more time
and expense from fund management, reducing the
financial return of the fund, and thus making venture
funding for global health more difficult [21]. One ave-
nue for mitigating this in the future may be developing
third-party networks, knowledge resources, and techni-
cal assistance programs to support investees – these
along with national funds can augment services the
investor can provide.
Al o o ka tt h ef i r m s ’ investments suggests that they
had non-trivial health impact, but how much is difficult
to quantify. Metrics for health impact are an area for
further research. Acumen Fund, as a social investment
firm, has done the most to attempt to develop metrics
for its social returns, including health impact.
The investment strategy itself was not an uncon-
strained choice, but rather an evolved compromise dri-
ven by fund size, local investment pipeline, and the
mandate and expectations of investors. Many opportu-
nities were not available locally, and would not have
been in the short term even if additional funds had been
available. All this underscores the importance of map-
ping local strengths and support mechanisms, to gener-
ate a data-driven landscape within which realistic
venture funding models can be designed.
For future funds, social and financial goals of investors
along with a data-driven landscape of the characteristics
of investment opportunities will guide investment strat-
egy. This includes return expectations for invested capi-
tal; the amounts, stages, and conditions of investment;
the third-party support required before investments are
made; and market assessments of technologies, includ-
ing affordability and ability to compete with existing
technologies.
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The investor scale and type is a key design considera-
tion, and we consider several natural possibilities below.
Private-sector financing: A pure private VC approach
to health R&D is unlikely to work for several reasons:
time and expense required to identify and support
investees; a relatively sparse pool of potential investees;
difficulty in exiting investments; location and R&D risk;
and opportunity costs as compared to venture invest-
ments in other sectors and locations. However, the pri-
vate VC model may be relevant for late-stage, smaller
investments such as medical devices to facilitate health-
care delivery – possibly linked with existing healthcare
funds like the $57M Aureos fund which is investing in
healthcare delivery such as clinics, for which there is
established demand in numerous African countries [22].
Such delivery-facilitating investments could be similar to
that made by APIDC-VE (India) in NeuroSynaptic’s
ReMeDi, for remote telemedical diagnosis; they could
also be import substitutions to make or modify com-
monly-used, commodity medical products locally or
more cheaply.
Institutional financing: Financing raised from various
sources and disbursed for research institutions has sup-
ported commercialization in the developed world, such
as Karolinska Development linked with the Karolinska
Institute (Sweden) – a roughly $250 million (USD) fund
with a life sciences focus. In Kenya, KEMRI constructed
a manufacturing facility with Japanese funds to produce
blood kits for the local market (see the KEMRI paper in
this BMC series). In Nigeria, NIPRD was the first in a
series of partners developing compounds for sickle cell
anemia (see the Niprisan paper in this BMC series).
However, even the largest African research institutions
appear to lack the size, experience, and local supporting
expertise to sustain institution-specific funds capable of
making larger investments. We hypothesize that institu-
tional financing may have a small and gradually increas-
ing role at a few select institutions with strong R&D
capacity and international partnerships that mitigate
risk.
National financing: The US VC industry has been
partly catalyzed by US government grants from organi-
zations like the National Institutes of Health. In the last
decade the South African government established sev-
eral funding programs to stimulate technology innova-
tion in the country, most notably the Innovation Fund
and the Biotechnology Regional Innovation Centres
(BRICs). These centers were charged with investing
national funds into technology innovation, providing
support services, investing at the high-risk early stage,
and de-risking projects for private sector players includ-
ing VCs. Recently, these programs along with several
others were drawn together to form the Technology
Innovation Agency, which hopes to better coordinate
the national funding of technology innovation in South
Africa. In Uganda, new government funds for support-
ing science-based innovation have been started (see the
Uganda paper in this BMC series). We hypothesize that
n a t i o n a lf i n a n c i n gh a sar o l et op l a yi np r o v i d i n ge a r l y -
stage funding, and enabling capital flow – galvanizing
private-sector and international venture funding, not
least by developing research ideas to a more “investable”
stage.
International financing: Virtually all the advanced
health-related projects presented in this BMC series had
involvement from a development or multilateral agency.
International partnerships allow African scientists to
raise the quality of their R&D and gain support. Compe-
titions such as the Grand Challenges Explorations initia-
tive of the Bill & Melinda Gates Foundation are open to
individuals worldwide; unconventional approaches are
supported by rapid response to grant applications, and
initial seed rounds of $100,000 with potential follow-on
funding of up to $1 million [23]. Other foundations
such as the Rockefeller Foundation and Wellcome Trust
have made significant investments into African life
sciences research initiatives. The Africa Enterprise Chal-
lenge Fund is making venture investments into
research-based agribusiness, renewable energy and rural
financial services, supported by developmental finance
organizations. Acumen Fund’s “social venture capital”
approach employs “patient capital” to nurture start-ups
with long-term support, with success to date in low-cost
healthcare delivery and manufacturing enterprises such
as BEEPZ (artemisinin) and A to Z Textile Mills (bed
nets). We hypothesize that international financing can
support science-based R&D where a commercial busi-
ness case may not be evident, especially if assisted by
appropriate metrics, milestones, networks, and
platforms.
Drawing on a range of actors
Successful venture funding for African science-based
health innovation will benef i tf r o mam u l t i - p a r t n e r
approach involving institutions, public and private sector
funding, successful African entrepreneurs, and interna-
tional agencies. A precedent may be the vaccine innova-
tion landscape, which involves: institutions and public-
private partnerships for R&D; public sector funding for
purchasing; international financing through e.g. GAVI,
UNICEF, the Bill & Melinda Gates Foundation, and
Advanced Market Commitments; and entrepreneurs for
local development, manufacturing, and delivery of key
vaccines. All players are necessary to create an incentive
landscape where venture financing can invest for high
financial and social returns.
More research and engagement with venture funding
groups is required to clarify incentives, partnerships,
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global health attractive, and to distinguish health invest-
ments for which venture funding will be appropriate
[24]. Establishing examples and eventually a track record
of success will be important; the five cases discussed
earlier may be modestly suggestive in this regard.
Further investigation is also required into the relative
roles of financial and social returns. Even the venture
funding groups discussed above had differing ratios of
financial to social return goals. These differences will
become yet more evident when a range of private-sector,
institutional, national, and international actors must
interoperate to support science-based health innovation.
We suggest developing better metrics for social and
health returns, and bringing such metrics into common
use by all actors, joining existing financial metrics. In
this way, a common language can be used when discuss-
ing the motivations of each actor, and the impact of
their respective actions.
Summary
From the case studies and analysis above, we believe
that there is an argument for using the venture
approach as one component of developing drugs, vac-
cines, diagnostics and medical devices in Africa. A life
sciences Africa VC fund should be structured to miti-
gate the risks discussed, attract for-profit private sector
funds, and provide managerial and financial oversight
and training to start-up companies. Attracting successful
African entrepreneurs from other sectors into the fund
will be valuable, as will tapping experienced venture
investors both domestically and abroad.
Based on the types of venture firms and fund risk
identified, an investor mix of for profit and not for
profit is a likely scenario, supported by domestic and
international financing sources – all of which can create
an incentive landscape which can both be attractive to
and benefit from venture funding.
Considerations of investment strategy and investor
scale and type will be critical. For example, an anchor
i n v e s t o rm i g h tb ean o tf o rp rofit institution that is
interested in health impact, but keen to establish a sus-
tainable life sciences commercialization model. This
anchor investor would mobilize seed funds that would
mitigate the real and perceived risk associated with
investing in early stage life sciences projects. A second-
tier investor group could be a consortium of larger
investors with the shared goal of providing “patient capi-
tal” to scale up the fund’s best opportunities. Local
investors and investees should also have a stake in the
fund’s success.
Funds should seek to involve private-sector partners at
later stages, to create self-sustaining flows of capital
f o c u s e do ni n n o v a t i o ni nA f r i c a .G o v e r n m e n tp o l i c i e s
should be aligned through R&D and investment support,
and general good governance. Drawing on a range of
actors will be essential.
A model to encourage commercialization of health
products in Africa through the development of “Conver-
gence Centers” has been proposed [25], and subse-
quently discussed in the broader context of S&T
development [26]. These Centers, which would co-locate
entrepreneurs, researchers and capital providers, would
be useful vehicles through which a venture funder could
identify technologies. They would act as a one-stop
shop for technologies that scientists in African countries
are developing, as well as a physical and virtual hub for
training and connecting talent.
Based on the cases and analysis in this paper, there is
a venture funding niche for science-based African health
innovation, with opportunities to make profits as well as
a social contribution. Such funds should be structured
to overcome the challenges identified, be sustainable in
the long run, attract for-profit private sector funds, have
measurable and significant health impact, and demon-
strate a different approach than aid-based international
development. While a range of supportive policies and
actors are required to tackle health challenges in Africa,
we believe the proposed venture approach can play a
significant part in encouraging local scientific and eco-
nomic development while tapping new sources of
funding.
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